Baxdela
| Chemical Name | delafloxacin |
| Dosage Form | Tablet (oral; 450 mg), injection (intravenous; 300 mg) |
| Drug Class | Antibacterials |
| System | Skin, Respiratory |
| Company | Melinta |
| Approval Year | 2017 |
Indication
- For the treatment of adults with the following infections caused by designated susceptible bacteria: Acute Bacterial Skin and Skin Structure Infections
- For the treatment of adults with the following infections caused by designated susceptible bacteria: acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia.